A.I. Burnasyan FMBC clinical bulletin. 2022 № 3
S.V. Kozyrev1, E.A. Ionova1, D.A. Sorochan1, V.N. Troyan2, A.N. Bobin2, I.V. Truten2, O.A. Rukavitsyn2
Features of Radiological Diagnosis of Hemorrhages in Foci of Brain Lesions in Oncohematological
Pathology. Clinical Observation
1Burnasyan State Research Center – Federal Medical Biophysical Center of Federal Medical Biological Agency
2The N.N. Burdenko Main Military Clinical Hospital Ministry of Defense of the Russian Federation
Contact person: Kozyrev Sergey Vladimirovich: serzh.kozyrev.1975@mail.ru
Abstract
The acute myeloid leukemia (AML) is the malignant transformation and uncontrolled proliferation of abnormally differentiated, long-lived myeloid progenitor cells cause a large number of blast cells in the circulating blood and replacement of normal bone marrow with tumor cells, as well as damage to other organs and systems. Neurological disorders in AML diseases are among the secondary lesions of the nervous system. Morphologically, neuroleukemia is characterized by multifocal leukemic infiltrates and disorders of the myelination of nerve fibers. The formation of leukemic foci in the medulla leads to an increase in intracranial pressure, compression of cerebral and spinal structures, loss of functions of the affected area. In such situations, computed tomography of the brain may reveal lesions of the brain substance, leukemic infiltration of the meninges of the brain, intracranial hemorrhages, and cerebral infarctions.
Keywords: аcute myeloid leukemia, cerebral hemorrhage, computed tomography
For citation: Kozyrev SV, Ionova EA, Sorochan DA, Troyan VN, Bobin AN, Truten IV, Rukavitsyn OA. Features of Radiological Diagnosis of Hemorrhages in Foci of Brain Lesions in Oncohematological Pathology. Clinical Observation. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2022.3:61-64. (In Russian) DOI: 10.33266/2782-6430-2022-3-61-64
REFERENCES
1. Estey E., D.hner H. Acute Myeloid Leukaemia. Lancet. 2006;368;9550:1894–1907.
2. Bharucha J., et al. Prognostic Factors for Clinical Outcomes of Patients with Central Nervous System Leukemia. Hematol Oncol. Stem. Cell. Ther. 2020;14;3:240-245.
3. Yao H., et al. Leukaemia Hijacks a Neural Mechanism to Invade the Central Nervous System. Nature. 2018;560;7716:55–60.
4. De Kouchkovsky I., Abdul-Hay M. Acute Myeloid Leukemia: a Comprehensive Review and 2016 Update. Blood Cancer J. 2016;6;7:e441.
5. Gruber T.A., Zwaan C.M. Central Nervous System Disease in Pediatric Acute Myeloid Leukemia. Pediatr Blood Cancer. 2017;64;12.
6. D.hner H., et al. Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations from an International Expert Panel, on Behalf of the European Leukemia Net. Blood. 2010;115;3:453–474.
7. Del Principe M.I., et al. Involvement of Central Nervous System in Adult Patients with Acute Myeloid Leukemia: Incidence and Impact on Outcome. Semin. Hematol. 2018;55;4:209–214.
8. Heidari N., et al. Central Nervous System Niche Involvement in the Leukemia. Clin. Transl. Oncol. 2016;18;3:240–250.
9. Hannon M., et al. Chronic Myelomonocytic Leukemia with Central Nervous System Involvement. Leuk. Lymphoma. 2018;59;9:2267–2268.
10. Barredo J., Ritchey A.K. Controversies in the Management of Central Nervous System Leukemia. Pediatr Hematol Oncol. 2010;27;5:329–332.
11. Mauermann M.L. Neurologic Complications of Lymphoma, Leukemia, and Paraproteinemias. Continuum (Minneap Minn). 2017;23;3(Neurology of Systemic Disease):669–690.
12. Pinnix C.C., et al. Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2018;102;1:53–58.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 01.08.2022. Accepted for publication: 28.08.2022